Head-To-Head Review: Heron Therapeutics (NASDAQ:HRTX) vs. Sol-Gel Technologies (NASDAQ:SLGL)Defense World · Sep 21, 2026
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 10, 2026
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research · Aug 10, 2026
Heron Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 10, 2026
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026GlobeNewsWire · Jul 27, 2026Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.01 | -$0.03 | Miss |
| May 11, 2026 | -$0.03 | -$0.04 | Miss |
| Feb 26, 2026 | -$0.03 | -$0.02 | Beat |
| Nov 4, 2025 | -$0.01 | -$0.05 | Miss |
| Aug 8, 2025 | -$0.01 | -$0.02 | Miss |
| May 6, 2025 | -$0.01 | $0.01 | Beat |